India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
disclaimer NO INFORMATION WITHIN THIS DOCUMENT SHOULD BE TAKEN FOR GRANTED. Any statement or premise not backed by a real logical definition or a verifiable reference may be invalid, erroneous, or a ...
More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, a setup that ...
Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results